ENO2 and neoplasm: Short-term efficacy, adverse reactions, immune function, tumor marker cytokeratin 21-1 (CyFRA21-1), carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and circulating tumor cell (CTCs) levels were compared between 2 groups.